Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection
2018 ◽
Vol 20
(9)
◽
pp. 2113-2120
◽
Keyword(s):
Β Cell
◽